TABLE 2.

Susceptibilities of gram-negative bacteria isolated from hospitalized patients with potentially complicated urinary tract infections in four European countries, Canada, and the United States to antimicrobials^a

Organism	Antimicrobial agent	France		Germany		Italy		Spain		Canada		United States
		No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible	No. of isolates	% Susceptible
E. coli	Cefotaxime	9,062	99.3	5,447	98.9	3,944	95.4	1,570	97.8	4,628	96.8	9,821	98.3
	Ceftazidime	8,498	98.6	2,474	98.4	4,001	94.1	1,538	98.5	9,025	98.6	15,593	96.7
	Ceftriaxone	1,167	99.2	906	99.7	1,440	96.9	NAb	NA	7,593	98.2	19,590	98.2
	Ciprofloxacin	6,045	91.0	4,017	79.4	4,112	74.8	1,105	70.3	10,060	89.4	22,440	89.7
	Gentamicin	9,548	95.4	4,863	93.0	5,268	89.4	1,621	88.4	10,903	94.2	27,780	94.2
	TMP-SMX	9,450	78.0	5,357	67.4	5,275	69.4	1,667	61.7	11,433	82.7	27,890	80.4
K. pneumoniae	Cefotaxime	1,143	94.7	1,162	92.9	789	85.0	171	95.3	1,453	97.8	3,416	93.6
	Ceftazidime	1,090	92.6	559	85.7	987	77.5	169	95.3	2,725	97.7	5,512	90.3
	Ceftriaxone	NA	NA	84	98.8	240	74.2	NA	NA	2,173	98.2	6,914	94.3
	Ciprofloxacin	771	87.4	921	80.8	996	88.0	71	91.5	3,024	93.5	7,565	90.2
	Gentamicin	1,148	97.7	1,111	90.4	1,013	87.3	173	89.6	3,265	96.9	9,396	93.8
	TMP-SMX	1,141	84.9	1,151	77.8	1,015	73.8	173	83.8	3,393	90.5	9,402	87.1
K. oxytoca	Cefotaxime	624	97.3	564	87.1	50	90.0	72	94.4	322	96.9	580	93.3
	Ceftazidime	592	98.8	229	93.0	101	87.1	71	100	592	98.8	987	93.1
	Ceftriaxone	57	86.0	NA	NA	63	93.7	NA	NA	491	98.4	1,113	90.2
	Ciprofloxacin	432	88.7	439	74.7	108	88.0	55	89.1	660	95.8	1,325	87.8
	Gentamicin	638	94.7	542	95.8	108	96.3	74	97.3	710	96.8	1,559	93.1
	TMP-SMX	638	91.7	555	74.6	108	87.0	75	85.3	746	95.8	1,566	89.0
P. mirabilis	Cefotaxime	1,684	98.8	1,406	99.2	1,110	63.6	211	100	964	98.8	1,997	99.7
	Ceftazidime	1,574	99.0	713	98.9	1,322	84.1	209	99.5	1,955	99.2	2,989	98.8
	Ceftriaxone	114	100	66	98.5	280	85.0	NA	NA	1,670	99.4	4,056	99.5
	Ciprofloxacin	1,192	81.8	1,222	82.0	1,349	64.6	129	78.3	2,176	88.8	4,443	81.5
	Gentamicin	1,729	93.2	1,275	88.9	1,364	57.3	216	86.6	2,325	94.2	5,515	90.9
	TMP-SMX	1,711	78.4	1,372	64.8	1,363	45.5	221	64.3	2,401	79.1	5,531	81.6
Other Enterobacteriaceae	Cefotaxime	2,574	69.2	1,561	78.7	970	61.2	251	79.7	1,320	82.5	4,010	75.2
	Ceftazidime	2,495	65.9	734	75.3	1,178	58.7	253	79.4	2,649	86.0	6,415	74.0
	Ceftriaxone	294	46.3	130	88.5	297	62.3	NA	NA	2,213	86.9	7,405	77.8
	Ciprofloxacin	1,790	55.4	1,216	73.5	1,198	55.8	153	83.7	2,956	83.6	8,069	78.9
	Gentamicin	2,591	83.0	1,382	89.0	1,215	70.7	261	89.7	3,185	91.6	9,844	88.5
	TMP-SMX	2,572	73.7	1,553	80.4	1,223	68.7	265	84.9	3,294	86.0	9,848	83.4

^aTo estimate antimicrobial susceptibilities among patients with complicated urinary tract infections, isolate specimen sources were limited to invasive specimen sources (catheterized urines, suprapubic bladder aspirates, nephrostomy, cystoscopic urine aspirates, and ureter; clean-catch urine and catheter tip isolates were excluded) from ICU and non-ICU inpatients, both males and females ≥18 years of age. The “Other Enterobacteriaceae” category was created for complicated urinary tract infection isolates to include Citrobacter spp., Enterobacter spp., Providencia spp., and Serratia spp. Data are cumulative for 2000 to 2001.

^bNA, not available, <50 results were available.